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Molecular imaging mass spectrometry (IMS) is a recently developed method for direct determina-
tion of spatial distribution of biopolymers, preferably proteins on cell surface and tissues. Imaging
mass spectrometry data are mainly based on Matrix-Assisted Laser Desorption/Ionization – Time
of Flight (MALDI TOF). The MALDI TOF based imaging mass spectrometry was applied for
determination of changes in kidney tissue of sensitive mice after poisoning with aristolochic acid I.
The second application presented here were changes in the gastric tissue in mice after infection
with Helicobacter pylori, as a model of gastric cancer in humans caused by this pathogen microor-
ganism. Molecular imaging mass spectrometry can be applied in medicine, mostly for identificati-
on of candidate biomarkers for malignant and non-malignant diseases. Furthermore, imaging MS
has almost unlimited capacity in agriculture, food technology and biotechnology, e. g. for monito-
ring, process development and quality control of manufactured tissue of animal, plant and micro-
bial origin.
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Introduction
Developments in mass spectrometry in the last twenty years
allow analysis of solid state materials and numerous appli-
cations have emerged in diverse fields such as biotechno-
logy, medicine, microelectronics, material science, geoche-
mistry and surface analysis (Reviewed in Reference 1). The
increasing interest in imaging mass spectrometry is due to its
ability for parallel detection of multiple analytes, gathering
of exact molecular masses at the same time to record spatial
distributions of a wide range of small molecules, but also
large biopolymers such as proteins and polysaccharides,
and to perform the analyses on native samples without la-
belling. Structural data can also be obtained by performing
MS/MS.2 Additionally, continuing improvements in all these
aspects, in software and hardware of the instrument are the
reason for increasing interest in this method.
Molecular Imaging Mass Spectrometry
The possibility of direct determination of the spatial distri-
bution of chemical components in cells and tissues makes
imaging mass spectrometry extremely interesting for appli-
cations in biology, biotechnology and medicine. With an
appropriate sample preparation, images of distributions of
small molecules, drugs and other organic compounds, but
also images of macromolecular components and structures
such as proteins, carbohydrates and lipids can be obta-
ined.1–3 Most imaging mass spectrometry data are based
either on Matrix-Assisted Laser Desorption/Ionization
(MALDI) or Secondary Ion Mass Spectrometry (SIMS).2,4
These two techniques offer different capabilities. MALDI
can record the spatial distribution of high mass molecules,
e. g. proteins using the specific molecular ions. Typical spa-
tial resolution is about 25 m, but recently 10 m sources
are available. SIMS is able to provide high spatial resolution
images in the sub-micron range.2,5 There are some im-
pressive applications of SIMS for the imaging of small mo-
lecules1,5,6 but the molecular ion mass range of this tech-
nique is much lower than that of MALDI, and most imaging
experiments use ions of m/z < 500.2 The m/z range for
MALDI is one to two orders of magnitude higher, and that is
why it is the method of choice for recording intact poly-
peptide and protein distributions. By use of this method,
proteins can be analyzed directly from tissue sections, and
their distribution can be determined.3,7,8 The overview of
the imaging mass spectrometry experiment is shown in
Fig. 1.
Molecular imaging spectrometry can be applied for patho-
logical studies and for biomarker analysis.3,7–10 It has been
applied to investigate proteome changes in different tumors
such as glioblastoma,3 colon tumors,11 liver metastasis,12 in
Alzheimer disease,10 in nefrotoxicity induced by antibio-
tics,13 during mouse prostate development,9 nervous tis-
sue14 etc. There are two approaches for direct tissue mass
spectral analysis: “profiling” or “imaging”. Molecular ima-
ging MS is the acquisition of complete mass spectra from
each spot on the surface of the analyte (e. g. tissue section,
plant leaf, other organic or inorganic materials) without
knowing about the structure of the molecules desorbed and
ionised. Molecular profiling MS is the acquisition of a part
or a small m/z region of a mass spectrum from each spot on
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the surface of the analyte knowing the structure of the mo-
lecules desorbed and ionised, i. e. searching for the ion with
a particular m/z value across the surface. Molecular imaging
and profiling is nowadays mostly done with cluster ions as a
primary beam because these beams generate sufficient se-
condary molecular ions.1–3
For imaging mass spectrometry, sample preparation is a key
step in the analytical procedure.3,14,15 Any molecular degra-
dation, or other reaction, e. g. protein–protein interaction
and/or aggregation that occurs in the time between sample
collection and analysis can influence the results. Samples
can be prepared using several protocols such as direct
analysis of frozen sections,3,16 isolation of individual cells by
laser-capture microdissection or contact blotting of a tissue
on a membrane target.17 The most used method is the ap-
plication of the tissue section onto a gold coated or stainless
steel target plate, coating with a matrix solution, drying and
introduction into the MALDI mass spectrometer.2,3,18 Cor-
responding software for the instrument control and evalua-
tion is commercially available. Molecular images are crea-
ted from a raster over the surface of the sample with
consecutive laser spots. The image resolution depends on
the number of spots. The molecular mass range is between
500 and 80000. However, the upper limit for lower abun-
dant proteins is about 30000 D (for method description cf.
References 2, 3 and 18). There are new instruments being
developed to improve spatial resolution, molecular sensiti-
vity and speed of the analysis. The high-resolution images
on the order of 10 m18,19 and down to 4 m20 are reported,
but these instruments are still in the early stage of deve-
lopment.18
A direct comparison between the protein and peptide dis-
tribution and cellular morphology determined by histology
is an important step on the path to the discovery of cell
specific biomarkers.21 The compatibility of several well-
-established tissue staining protocols with the MALDI MS
analyses has already been demonstrated.21
Application
Kidneys from aristolochic acid treated mice
Aristolochic acid (AA) present in Aristolochia plants are to-
xins responsible for Chinese Herbs Nephropathy (CHN).
This type of rapidly progressive interstitial renal fibrosis re-
ported in a group of Belgian women after the introduction
of medicaments based on Chinese herbs.22 The disease is
characterized by early, severe anemia and mild tubular pro-
teinuria, and renal interstitial fibrosis. Urothelial malignancy
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F i g. 1 – Overview of the imaging mass spectrometry experiment using MALDI TOF MS
(Taken from: Van de Plas et al. (2007) Pacific Symp. on Biocomputing 12:458-469.)
S l i k a 1 – Prikaz eksperimenta “imaging mass spectrometry” uz uporabu MALDI TOF MS
(Preuzeto iz: Van de Plas et al. (2007) Pacific Symp. on Biocomputing 12:458-469.)
of the upper urinary tract develops subsequently in almost
half of the patients. Exposure to AA was confirmed by the
detection of AA-DNA adducts in the kidney tissue samples
from CHN patients.23 Recently, Grollman et al.24 presented
strong indications, that dietary poisoning by AA is also re-
sponsible for Endemic (Balkan) nephropathy (EN) and asso-
ciated urothelial cancer. This renal disease affects the rural
population of Southeastern Europe, in Bosnia and Herzego-
vina, Bulgaria, Croatia, Serbia and Romania.25 The main
features of human CHN, renal intestinal fibrosis and urot-
helial malignancy have also been reproduced in rats.26 Sato
and coworkers27 reported that mice belonging to the sensi-
tive C3H/He strain, when treated with AA rapidly develo-
ped nephropathy. AA is a mixture of structurally related
nitrophenanthrene carboxylic acids, containing two major
components – aristolochic acid I (AA I) and aristolochic acid
II (AA II) (see Ref. 28 and Fig. 2). Investigation using purified
AA I and AA II revealed that AA I induced strong nephroto-
xicity in mice, and that AA II resulted in mild nephrotoxi-
city. The other investigated components, AA IVa and aristo-
lactam proved as nontoxic.27
Gastric carcinogenesis induced by H. pylori
Prior infection with H. pylori is the most important risk fac-
tor for the development of gastric cancer. Dr. Steven Moss
from the Department of Gastroenterology, Rhode Island
Hospital, Providence, RI, USA developed p27-deficient
mouse model, sensitive to H. pylori infection. The p27 pro-
tein is a cell cycle regulator and it has been postulated as a
link between chronic H. pylori infection and gastric can-
cer.29 The development of this mouse model of H. pylori in-
duced gastric cancer provides an important step forward in
dissecting pathogenesis of gastric cancer. The pattern of
protein changes in gastric epithelial cells of p27-deficient




Mouse model, introduced by Sato at al.27 was used to com-
pare the effects of two forms of AA: AA I and AA II. The ani-
mals were treated with AA (1.8 mg kg–1 day–1, i. p.) for 11
days and sacrificed. The histochemistry was performed by
Dr. Paul McMillan (CORE Laboratory, Rhode Island Hospi-
tal, Providence, RI).
P27-deficient mice were bred, housed and infected with H.
pylori as previously described29, and sacrificed after 15
weeks, the time point that corresponds to the start of mild
chronic gastritis. Uninfected control p27-deficient mice
were euthanized at the same time point as control. At ne-
cropsy the stomach was removed and split longitudinally
into 3 equal portions for (1) formalin fixation and embed-
ding in paraffin for routine histology (Hematoxylin and Eo-
sin staining), (2) quantitative assessment of H. pylori bur-
den, and (3) frozen sectioning for molecular imaging mass
spectrometry.*
Sample preparation and molecular imaging
mass spectrometry
Sample preparation and histochemistry were performed by
Dr. Paul McMillan (CORE Laboratory, Rhode Island Hospi-
tal, Providence, RI). Mouse kidneys were harvested and im-
mediately frozen in liquid nitrogen. Tissue sectioning of the
frozen sample was carried out using a cryostat. Tissue secti-
ons ranging from 5 m to 15 m were mounted onto the
surface of an electrically conductive ITO glass slide (Bruker
Corp. Billerica, MA, USA) and allowed to adhere to the sur-
face simply by surface tension. Tissue sections were rinsed
to remove salts by a t = 30 s immersion in j  70 % ethanol
followed by j = 96 % ethanol rinse for t = 30 s. The orga-
nic matrix sinapinic acid (Sigma Aldrich, St. Louis, MO,
USA) which is required for the ionization of molecular sig-
nals was applied to the tissue surface automatically with the
ImagePrep (Bruker Corp.). The matrix mass concentration
of  = 10 mg mL–1 was dissolved in j = 60 % acetonitrile
containing j = 0.2 % trifluoroacetic acid (Sigma Aldrich).
The ImagePrep consumed approximately 2.5 mL of the
matrix, which completely covered the glass slide containing
multiple tissue sections. During this critical event of matrix
deposition, molecules within the tissue are extracted and
incor- porated into the matrix layer. Liquid droplets genera-
ted with the ImagePrep are on average d = 25 m in di-
ameter, which therefore limits the experimental imaging
resolution to this droplet size when considering de-localiza-
tion of molecules within liquid droplet.
The mass analysis was performed with the Ultaflex III™
MALDI TOF MS instrument (Bruker Corp.) configured with
the smartbeam™ laser having a beam focus set at 30 m.
The mass range was scanned in linear mode from 600 Da to
30 kDa at a repetition rate of 200 Hz. For all tissue sections,
data was collected at a pixel resolution between 75–100
m.










F i g. 2 – Aristolochic acid (AA)
AA I: R1 = R2 = R4 = H, R3 = OCH3
AA II: R1 = R2 = R3 = R4 = H
S l i k a 2 – Aristolohijska kiselina (AA)
AA I: R1 = R2 = R4 = H, R3 = OCH3
AA II: R1 = R2 = R3 = R4 = H
* The experiments were performed in Dr. Steven Moss’ Laboratory (Rho-
de Island Hospital).
Results
Mouse kidneys treated with AA
Already after the second day of the treat-
ment, kidneys of AA I sensitive mice show
change in histological pattern (see Fig. 3).
Molecular image of same tissue is shown
in Fig. 4. After application of appropriate
matrix and laser-based ionization, mo-
lecules are flying towards detector. The ti-
me-of-flight of the molecules depends on
their mass of fragment and charge (m/z va-
lue, see lower part of Fig. 3). After scan-
ning of the complete surface of the
specimen and analysis by corresponding
software, a molecular image for a defined
m/z value can be constructed (for the m/z
= 7,791, see upper part of Fig. 4). Distri-
bution of peaks with three different m/z
values (1,495; 3,751 and 4,979 respecti-
vely) is given in Fig. 5. As shown in the two
last figures (Figs. 4 and 5), distribution of
these molecules is different in kidneys of
AA I treated and AA I untreated mice.
Mouse gastric mucosa after infection
with H. pylori
Fig. 6 shows digital images of gastric mu-
cosa of control and H. pylori infected
mice. MALDI molecular imaging of same
specimens shows significant changes in
distribution of two proteins with m/z va-
lues of 9,962 and 14,047 (Fig. 7). As
shown in the upper part of Fig. 7, the pro-
tein with the m/z value of 9,962 is almost
completely absent in the mucosa of
infected mice. It can be anticipated that
studies with this cutting-edge, new
technology will help dissect the cellular
pathways altered during human gastric
carcinogenesis caused by this pathogenic
bacteria and define novel biomarkers of
risk and prognosis in gastric cancer.
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F i g. 3 – Histological image of mouse kidney after removal of MALDI-matrix, Hema-
toxylin and Eosin staining, original magnification 10×. Left – control, right – AA I treated.
S l i k a 3 – Histološka slika mišjega bubrega nakon uklanjanja MALDI-matriksa, bojeno
hematoksilinom i eozinom, uveæanje 10×. Lijevo – kontrola, desno – tretiran s AA I.
F i g. 4 – Molecular mass spectrometric imaging of mouse kidney. Left – control, right
– AA I treated. Upper part – distribution of the ion with a m/z value of m/z = 7,791 (corre-
sponding to the molecular ion of a large peptide/small protein). Lower part – Full positive
ion MALDI mass spectrum
S l i k a 4 – Molekulski maseno-spektrometrijski prikaz mišjega bubrega. Lijevo –
kontrola, desno tretiran s AA I. Gornji dio – raspodjela iona s m/z = 7.791 (odgovara mo-
lekulskom ionu velikoga peptida ili niskomolekulskog proteina). Donji dio – Kompletan
MALDI maseni spektar.
F i g. 5 – Molecular mass spectrometric image of
mouse kidney. Spatial distribution of ions with the
following m/z values: 1,495, 3,751 and 4,979 (cor-
responding presumably to molecular ions of pepti-
des or small proteins). Left – control, right – AA I
treated. Upper part – distribution of peaks with diffe-
rent m/z values.
S l i k a 5 – Molekulski maseno-spektrometrijski
prikaz mišjega bubrega. Prostorna raspodjela iona s
m/z velièinama: 1.495, 3.751 i 4.979 (za molekulske
iona peptida ili niskomolekulskih proteina). Lijevo –
kontrola, desno tretiran s AA I. Gornji dio – raspo-
djela pikova s razlièitim vrijednostima m/z.
F i g. 6 – Digital images of mouse gastric mucosa. Left – con-
trol, right – 15 weeks after H. pylori infection
S l i k a 6 – Digitalni prikaz mukoze Þeluca u miša. Lijevo – kon-
trola, desno – 15 tjedana nakon infekcije s H. pylori.
F i g. 7 – Molecular mass spectrometric image of mouse gastric
mucosa. Spatial distribution of ions with the following m/z values:
9,962 (upper part) and 14,047 (lower part, both corresponding
presumably to molecular ions of proteins). Left – control, right – 15
weeks after H. pylori infection.
S l i k a 7 – Molekulski maseno-spektrometrijski prikaz mukoze
Þeluca u miša. Prostorna raspodjela iona s iznosima m/z: 9.962
(gornji dio) i 14.047 (donji dio, u oba sluèaja za molekulske ione
proteina). Lijevo – kontrola, desno 15 tjedana nakon infekcije s H.
pylori.
Conclusions
– Molecular imaging is an emerging technique between
histopathology and mass spectrometry.
– This technique is now applied in medicine, mostly for
identification of candidate biomarkers for several malignant
and non-malignant diseases.
– Furthermore, this technique has also almost unlimited
capacity for application and biomaterial characterization in
food technology and biotechnology, mostly for process de-
velopment and quality control of manufactured tissue of
animal and plant origin.
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SAÝETAK
Masena spektrometrija molekulskog oslikavanja
Dj. Josiæa,c i S. Kovaèa,b
Razvoj masene spektrometrije u posljednjih 20 godina i primjena ove metode u analitici makro-
molekula, prije svega proteina i ugljikohidrata, otvorio je nove perspektive za uporabu ove meto-
de u medicini, biotehnologiji i ostalim biodisciplinama. Ova se metoda moÞe primijeniti i u
novim podruèjima, kao što su mikroelektronika, geokemija i površinska analitika, posebice nano-
tehnologija.1
Imaging mass spectrometry (IMS) je jedna vrsta sinteze dviju tehnika, histokemije i masene spek-
trometrije. Ova metoda omoguæava optièki prikaz rasporeda raspodjele malih i velikih molekula
u uzorku, pa èak i makromolekula kao što su proteini i polisaharidi.2 Optimalizacija masene spek-
trometrije, ali takoðer i veliki napredak u razvoju instrumentacije dodatni su razlog za sve veæi in-
teres za ovu metodu u mnogim interdisciplinarnim podruèjima medicine, biotehnologije, ali i
anorganskim tehnologijama i znanosti o materijalima (material science).1
Imaging MS daje moguænost izravnog praæenja prostorne raspodjele molekula u stanicama ili tki-
vu. Za dobivanje molekularne distribucije u adekvatno pripravljenom uzorku najèešæe se prim-
jenjuju Matrix-Assisted Laser Deionisation (MALDI) Time of Flight (TOF) ili Secondary Ion Mass
Spectrometry (SIMS)4. Pomoæu MALDI TOF dobiva se slika prostorne raspodjele velikih moleku-
la, prije svega proteina. Rezolucija ove metode je 25 m, što je još uvijek nedovoljno da se prati
raspored komponenata na razini stanice, ali novi instrumenti omoguæavaju i bolju rezoluciju u
podruèju od oko 10 m.
SIMS je metoda koja se primjenjuje za praæenje prostorne raspodjele malih molekula, najèešæe
biološki aktivnih supstancija.1,5,6 MALDI TOF je pak metoda izbora za analizu prostorne distribu-
cije makromolekula, najèešæe proteina i polipeptida.
IMS se do sada primjenjivala za patološke studije i analizu biomarkera,3,7–10 za analizu tumora,
kao glioblastoma,3 karcinoma debeloga crijeva,11 metastaza u jetri,12 kod praæenja promjena u
moÞdanom tkivu kod Alzheimerove bolesti10 i ostalih promjena u Þivèanom tkivu,14 kod nefrotok-
siciteta13 itd.
Na sl. 1 prikazan je princip odreðivanja raspodjele makromolekula pomoæu MALDI TOF masene
spektrometrije. Nakon rezanja tankog sloja i fiksiranja, tkivu se dodaje odreðena supstancija
(matrix) koja omoguæava optimalnu ionizaciju i mobilizaciju makromolekula. Vrijeme letenja
(time of flight) je obrnuto proporcionalno vrijednosti kvocijenta fragmentirane mase i (pozitivnog)
naboja m/z. Raèunalo automatski upravlja sveobuhvatnim snimanjem površine (screening) i daje
površinsku sliku rasporeda molekule odreðene m/z vrijednosti. To se vidi i na slici 4 koja daje ras-
podjelu molekule s m/z vrijednosti od 7.791 u uzorku bubrega miša otrovanog aristolohijskom ki-
selinom I (AA I). Na slici 4 je prikazan raspored triju razlièitih molekula u istim uzorcima.
Model miša tretiranog s AA I i AA II je izoliran jer postoje opravdani pokazatelji da je kronièno tro-
vanje ovom suspstancijom jedan od uzroka endemskog nefritisa (EN). Endemski nefritis je kroniè-
no oboljenje bubrega, proširen u endemskim podruèjima u donjem toku rijeke Dunava. U
Hrvatskoj se ova bolest pojavljuje u odreðenim selima Brodske Posavine zapadno od Slavonskog
Broda.
Bakterija Helicobacter pylori je uzroènik infekcije Þeluca, koja dovodi do kroniènoga gastritisa i,
godinama nakon infekcije, do karcinoma. Model miša, inficiranog s Helicobacter pylori pokazuje
da 15 dana nakon infekcije dolazi do promjene u raspodjeli proteina, i da protein s m/z vrijednos-
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List of symbols
Popis simbola
d – average diameter, m
– prosjeèni promjer, m
m – molecular mass, Da, kDa
– molekulska masa, Da, kDa




 – mass concentration, mg mL–1
– masena koncentracija, mg mL–1
j – volume fraction, %
– obujmni udjel, %
ti 9,962 gotovo nestaje s maseno-spekrometrijskog profila. Ovi pokusi su prvi koraci u definiranju
molekulskih promjena kod karcinogeneze Þeluca, definiciji novih biomarkera za otkrivanje rizika
i prognozu kod ove zloæudne bolesti.
– IMS je tehnika kojom se kombinira histologija i masena spektrometrija MALDI TOF.
– IMS trenutaèno nalazi primjenu u medicini, za identifikaciju kandidata za biomarkere za ma-
ligne i druge bolesti.
– Kao tehnika, imaging mass spectrometry ima velike perspektive za primjenu u agrikulturi,
prehrambenoj tehnologiji i biotehnologiji i to za kontrolu kvalitete i praæenja promjena u biljnim,
Þivotinjskim tkivima i mikrobnim stanicama tijekom procesa proizvodnje.
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